Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19

Clin Infect Dis. 2024 Jul 19;79(1):108-110. doi: 10.1093/cid/ciae105.

Abstract

Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more messenger RNA vaccine doses (adjusted hazard ratio, 0.22; 95% confidence interval, .19-.24). Eligible adults, including those previously vaccinated, should be considered for COVID-19 antiviral treatment.

Keywords: COVID-19; SARS-CoV-2; nirmatrelvir-ritonavir; vaccination.

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents* / administration & dosage
  • Antiviral Agents* / therapeutic use
  • COVID-19 Drug Treatment
  • COVID-19 Vaccines* / administration & dosage
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Female
  • Hospitalization* / statistics & numerical data
  • Humans
  • Lactams
  • Leucine / analogs & derivatives
  • Leucine / therapeutic use
  • Male
  • Middle Aged
  • Nitriles
  • Proline
  • Ritonavir* / administration & dosage
  • Ritonavir* / therapeutic use
  • SARS-CoV-2* / immunology
  • Vaccination / statistics & numerical data

Substances

  • Ritonavir
  • Antiviral Agents
  • COVID-19 Vaccines
  • nirmatrelvir
  • Leucine
  • Lactams
  • Nitriles
  • Proline